Metformin Improves Glycemic Control and Postprandial Metabolism and Enhances Postprandial Glucagon-Like Peptide 1 Secretion in Patients With Type 2 Diabetes and Heart Failure: A Randomized, Double-Blind, Placebo-Controlled Trial.
Vojtěch Melenovský, Eva Hošková, Kateřina Velebová, Jiří Veleba, Barry A Borlaug, Jan Benes, Ondřej Kuda, Tomáš Čajka, Markéta Segeťová, Lenka Thieme, Jan Kopecký, Jan Kopecký, Terezie Pelikánová, Martin Haluzík, Martin Hill, Hana Kahleová
{"title":"Metformin Improves Glycemic Control and Postprandial Metabolism and Enhances Postprandial Glucagon-Like Peptide 1 Secretion in Patients With Type 2 Diabetes and Heart Failure: A Randomized, Double-Blind, Placebo-Controlled Trial.","authors":"Vojtěch Melenovský, Eva Hošková, Kateřina Velebová, Jiří Veleba, Barry A Borlaug, Jan Benes, Ondřej Kuda, Tomáš Čajka, Markéta Segeťová, Lenka Thieme, Jan Kopecký, Jan Kopecký, Terezie Pelikánová, Martin Haluzík, Martin Hill, Hana Kahleová","doi":"10.2337/cd24-0003","DOIUrl":null,"url":null,"abstract":"<p><p>This randomized trial tested the effect of metformin on glycemic control and cardiac function in patients with heart failure (HF) and type 2 diabetes while evaluating intestinal effects on selected gut microbiome products reflected by trimethylamine-N-oxide (TMAO) and gut-derived incretins. Metformin treatment improved glycemic control and postprandial metabolism and enhanced postprandial glucagon-like peptide 1 (GLP-1) secretion but did not influence cardiac function or the TMAO levels. Metabolic effects of metformin in HF may be mediated by an improvement in intestinal endocrine function and enhanced secretion of the gut-derived incretin GLP-1.</p>","PeriodicalId":39894,"journal":{"name":"Clinical Diabetes","volume":"43 1","pages":"23-32"},"PeriodicalIF":0.0000,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11739370/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Diabetes","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2337/cd24-0003","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
This randomized trial tested the effect of metformin on glycemic control and cardiac function in patients with heart failure (HF) and type 2 diabetes while evaluating intestinal effects on selected gut microbiome products reflected by trimethylamine-N-oxide (TMAO) and gut-derived incretins. Metformin treatment improved glycemic control and postprandial metabolism and enhanced postprandial glucagon-like peptide 1 (GLP-1) secretion but did not influence cardiac function or the TMAO levels. Metabolic effects of metformin in HF may be mediated by an improvement in intestinal endocrine function and enhanced secretion of the gut-derived incretin GLP-1.
这项随机试验测试了二甲双胍对心力衰竭（HF）和2型糖尿病患者的血糖控制和心功能的影响，同时评估了三甲胺- n -氧化物（TMAO）和肠道源性肠促胰岛素对肠道微生物组产物的影响。二甲双胍治疗改善血糖控制和餐后代谢，增强餐后胰高血糖素样肽1 （GLP-1）分泌，但不影响心功能或TMAO水平。二甲双胍在HF中的代谢作用可能是通过改善肠道内分泌功能和增强肠源性肠促胰岛素GLP-1的分泌来介导的。
期刊介绍：
The mission of Clinical Diabetes is to provide primary care providers and all clinicians involved in the care of people with diabetes with information on advances and state-of-the-art care for people with diabetes. Clinical Diabetes is also a forum for discussing diabetes-related problems in practice, medical-legal issues, case studies, digests of recent research, and patient education materials.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
